<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922129</url>
  </required_header>
  <id_info>
    <org_study_id>IIS-002-09</org_study_id>
    <nct_id>NCT00922129</nct_id>
  </id_info>
  <brief_title>Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer</brief_title>
  <official_title>A Prospective Randomized Pilot Study Examining the Role and Effectiveness of Conversion to Sirolimus Versus CNI Reduction in Renal Transplant Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Joseph's Healthcare Hamilton</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the role and effectiveness of conversion to
      sirolimus versus CNI reduction in renal transplant patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to support the optimal use of mTOR-inhibitor by providing data for the
      safe and effectiveness use with sirolimus. This study will take into account effectiveness
      aspects such as malignancy-free survival cancer by reducing the overall exposure to
      calcineurin inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study did not start up as planned.
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malignancy-free survival</measure>
    <time_frame>Months 3, 9, 15, 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function as measured by serum creatinine and calculated creatinine clearance (using the formula of Cockcroft-Gault)</measure>
    <time_frame>Weeks 1, 3, 6, Months 3, 6, 9, 12, 15, 18, 21 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone levels</measure>
    <time_frame>Months 6, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Months 6, 12, 18 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Conversion to sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcineurim inhibitor reduction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus (Rapamune)</intervention_name>
    <description>Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months</description>
    <arm_group_label>Conversion to sirolimus</arm_group_label>
    <other_name>RAPAMUNE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin (Neoral) or Tacrolimus (Prograf)</intervention_name>
    <description>Cyclosporin: 3-4 mg/kg, BID, PO, 24 months
Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months</description>
    <arm_group_label>Calcineurim inhibitor reduction</arm_group_label>
    <other_name>Cyclosporin: NEORAL</other_name>
    <other_name>Tacrolimus: PROGRAF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients ≤ 50 years in their post renal transplant follow-up;

          -  Biopsy confirmed prostate cancer;

          -  Stable renal function with GFR ≥ 40 mL/min.

        Exclusion Criteria:

          -  Patients with metastatic disease;

          -  Uncontrolled hyperlipidemia;

          -  Proteinuria &gt; 500 mg/day;

          -  Biopsy evidence of acute rejection within the past 3 months;

          -  Existence of any surgical or medical condition, other than the current transplant,
             which in the opinion of the investigator might significantly alter the absorption,
             distribution, metabolism or excretion of study medication;

          -  Patients with mental illness;

          -  Inability to cooperate or communicate with the investigator or unable to complete self
             administered questionnaires.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Kapoor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster Institute of Urology, McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster Institute of Urology - St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>January 13, 2014</last_update_submitted>
  <last_update_submitted_qc>January 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <name_title>Dr Anil Kapoor</name_title>
    <organization>McMaster Institute of Urology, McMaster University</organization>
  </responsible_party>
  <keyword>Sirolimus</keyword>
  <keyword>Calcineurin inhibitor</keyword>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

